Drug Database
Back to search

Belgium· BE-AMP-SAM505440-00

Cabometyx 60 mg

A cabozantinib product containing cabozantinib (s)-malate, registered in Belgium by Ipsen Pharma. The same ATC class is registered in 12 of our 19 countries.

ATC L01EX07

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCabometyx 60 mgATCL01EX07REGISTER NO.BE-AMP-SAM505440-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cabozantinib (s)-malateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cabozantinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EX07 (cabozantinib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search cabozantinib products by name

Cabozantinib · ATC L01EX07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cabozantinib costs, country by country.

Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cabozantinib · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$570.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Cabozantinib (S)-Malate
Manufacturer
Ipsen Pharma
Country
Belgium (BE)
ATC code
L01EX07
ATC class
Cabozantinib
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

  • be_apb
    3567559
  • be_apb
    7721582
  • be_apb
    4639357

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

544 interactions on record for cabozantinib.

Graded by severity as the source publishes them — 360 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cabozantinib against other medicinesHow interaction checks work

Cabozantinib · interactions on record

544 records

  • 360 severe
  • 179 moderate
  • 5 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cabozantinib in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cabozantinib products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Czechia · Cabozantinib Teva
  • Denmark · Cabozantinib Teva, Hasgobusno
  • Spain · Cabozantinib Sun
  • Finland · Cabozantinib Ratiopharm
  • Croatia · Kabozantinib Teva
  • Iceland · Cabometyx, Cometriq
  • Italy · Cabozantinib Teva
  • Liechtenstein · Cabometyx, Cometriq
  • Norway · Cabometyx, Cometriq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2b4a63e2-771b-4b6e-92c7-1183fab4ec30
GET /v1/drugs/2b4a63e2-771b-4b6e-92c7-1183fab4ec30?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Cabometyx 60 mg",
  "name_fr": "Cabometyx 60 mg",
  "name_nl": "Cabometyx 60 mg",
  "amp_code": "SAM505440-00",
  "strengths": [
    "60.0000",
    "46.6100"
  ],
  "pack_count": 4,
  "substances": [
    "Cabozantinib (S)-Malate",
    "Cabozantinib",
    "Lactose"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Cabozantinib",
  "authorisation_numbers": [
    "EU/1/16/1136/006",
    "EU/1/16/1136/005"
  ]
}
API referenceMCP serverPlans

See everything about cabozantinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console